CP, regarding your recent insightful posts, you had suggested a series of prospective "yes, no" questions that could be answered using what Wookie calls the APP platform. You started me thinking further on your point, I observe there are intermediate logic steps that may also indicate value from a Bavi applied "flagging" of tumor exposed PS or ES in apoptosis (think I wrote that technically right).
For the diagnostic capabilities that we are guessing about at this point:
1. Ability to detect existence of elevated exposed PS, ES or other "inside out" amino acids in cancer cells. Yes or No. My observation is that last week's announced proof of concept says yes to this ability with an apparent 100% success rate. 100% is a cool outcome.
2. Ability to do item one plus provide quantification of how much exposed PS or ES bio marking has occurred. The degree of indicated PS exposure being able to be quantified and calibrated to an indicator of the extent of cancer present seems like it would be a very useful tool for assisting the dosing of other therapies. Can PPHM APP tech do quantification? Yes or no. My guess is that quantification is a yes, but we don't know that for sure and one might expect more research would be needed to calibrate the significance of exposed PS/ES bio marking to cancer extent and therapeutic measures. That dynamic could proceed on the path PPHM has started but would be much accelerated if a partner came forward, IMO. For comparison, consider the current liver enzymes tests that can translate back to blood levels being "normal" and various degrees of elevation if the body is experiencing illness. The Bavi APP might create a similar diagnosis assisting tool for cancer therapeutics.
3. Ability to do items one or two plus provide a means for sorting cancer type being indicated by the biomarker. I observe that PS/ES exposure is common to all the cancers (by my understanding) as well as to some viruses. Sorting out which ones are present might be accomplished (I don't see how, but am working the logic sequence)but I observe that experience using the biomarkers might enable some general sorting to identify what is present. There would be enhanced value, if so, but research with a partner would certainly speed things along so that resources don't overly constrain the development.
4. Ability to do items one, two or three plus provide enhanced effectiveness of the applied cancer treatment itself. We already know that the Bavi studies were looking for benefits that might be delivered if the attachment of Bavi to inside out exposed PS/ES activated the body's own immune system to recognize the cancer cell or virus infected cells and get to work. Of course, the Bavi studies have not yet cleared past uncertainties of certain Beta Bodies being present and there are things about the technology I don't really understand. Last year's halt to the Phase 3 Bavi study indicates more is needed in research here. However, there is still a directional prospect of APP therapeutic value that needs to be checked out.
A general question for those that know the tech better than I: Can the Bavi analyticals be accomplished with just a blood sample and introduction of trace quantities of Bavi in a test lab to determine items 1 through 3 above or must a patient actually receive a Bavi treatment dose to exhibit the desired indicators in a blood sample? It would seem that a blood sample and lab work with Bavi would suffice for items one, two and maybe three. Maybe items 3 and 4 would require monitoring of a patient post Bavi treatment?
Just my chemical engineering, questioning mind at work..., no expertise on the subject matter under question.
Best wishes and IMO.
KT
AI
